Parlier et al developed the Lausanne-Bournemouth (LB) Score for patients with a primary myelodysplastic syndrome by combining cytogenetic information with the Bournemouth score of Mufti et al (see above). The score correlates with clinical progression and reflects the importance of the cytogenetic findings. The authors are from medical institutions in Lausanne and Bern, Switzerland.
Parameters of the Bournemouth score (Mufti et al, above):
(1) hemoglobin
(2) platelet count
(3) bone marrow blasts
(4) neutrophil count
|
Parameter |
Finding |
Points |
|
hemoglobin |
> 10 g/dL |
0 |
|
|
<= 10 g/dL |
1 |
|
platelet count |
> 100,000 /µL |
0 |
|
|
<= 100,000 /µL |
1 |
|
bone marrow blasts |
< 5% |
0 |
|
|
>= 5% |
1 |
|
neutrophil count |
> 2,500 /µL |
0 |
|
|
<= 2,500 /µL |
1 |
If the patient has CMML, the modified Bournemouth score of Worsley et al (above) was used. This is the same as the original Bournemouth score, except for:
|
Parameter |
Finding |
Points |
|
neutrophil count |
> 16,000 /µL |
1 |
|
|
2,500 to 16,000 per µL |
0 |
|
|
< 2,500 /µL |
1 |
total Bournemouth score =
= SUM(points for all 4 parameters)
The cytogenetic findings were scored as follows:
|
Cytogenetic Findings |
Score |
|
normal |
0 |
|
single cytogenetic defect |
1 |
|
double cytogenetic defect |
2 |
|
complex defects |
3 |
The Lausanne-Bournemouth (LB) score combines both the Bournemouth and cytogenetic scores as follows:
|
Parameter |
Finding |
Points |
|
Bournemouth score |
0 or 1 |
0 |
|
|
2, 3 or 4 |
1 |
|
cytogenetic score |
0 or 1 |
0 |
|
|
2 or 3 |
1 |
total LB score =
= (points for the Bournemouth score) + (points for cytogenetic findings)
Interpretation:
• minimum LB score: 0
• maximum LB score: 2
|
LB Score |
Risk Group |
18 Month Mortality Rate |
|
0 |
low |
7.1% |
|
1 |
intermediate |
60.1% |
|
2 |
high |
96.8% |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
